CT-048

N/A

Report date: 2023/06/01 20:00:46

Base Information

Drug NameCT-048
Drug Alias NameCT-048KJ-C1807KJ-C-1807
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionClaudin-18 splice variant 2 antagonists
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsPancreatic NeoplasmsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCarsgen Biomedicine (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPeking UniversityCarsgen Biomedicine (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsPancreatic NeoplasmsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A